Physician profile
Robert F Hunter
NPI 1588657522
$23,491.34
in general payments reported to CMS, 2019-2025
58 companies · $5,640 in 2025
The $5,640 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,660 · 2020: $908 · 2021: $2,736 · 2022: $3,486 · 2023: $3,825 · 2024: $4,236 · 2025: $5,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,287.52 |
| Education | $413.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,298.01 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $2,235.82 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Pbg Puerto Rico LLC | $1,896.01 | 2019-2025 | |
| Abbvie INC. | $1,723.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,359.70 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,314.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,269.93 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Genentech USA, INC. | $1,009.23 | 2021-2025 | Polivy, Lunsumio, Columvi |
| Eli Lilly Export S.A. Puerto Rico Branch | $953.64 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $944.46 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $608.00 | 2019-2025 | Ninlaro |
| Amgen INC. | $597.99 | 2019-2025 | Xgeva, Kyprolis, Lumakras |
| Pfizer INC. | $543.80 | 2019-2025 | |
| Incyte Corporation | $519.74 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Puma Biotechnology, INC. | $453.37 | 2020-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $423.78 | 2024-2025 | Xt Cdx |
| Exelixis INC. | $412.80 | 2019-2025 | Cabometyx |
| Pharmaessentia USA Corporation | $396.64 | 2022-2025 | Besremi |
| Astellas Pharma US INC | $353.71 | 2021-2025 | Xospata, Padcev, Vyloy |
| Eisai INC. | $351.18 | 2019-2025 | |
| Celgene Corporation | $341.03 | 2019 | |
| Beigene USA, INC. | $246.23 | 2021-2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $220.04 | 2019-2023 | Imbruvica |
| Mirati Therapeutics, INC. | $206.36 | 2023-2024 | Krazati |
| Bayer Puerto Rico INC. | $205.52 | 2023-2025 | Stivarga, Nubeqa, Vitrakvi |
| Janssen Biotech, INC. | $199.90 | 2021-2023 | Erleada |
| Verity Pharmaceuticals INC. | $186.38 | 2022-2025 | Trelstar, Akynzeo |
| Taiho Oncology, INC. | $175.14 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $162.37 | 2023-2025 | Libtayo |
| Sobi, INC | $159.10 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $149.51 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Adc Therapeutics America, INC. | $146.21 | 2022-2023 | |
| Seagen INC. | $144.58 | 2020-2023 | Tukysa, Padcev |
| Jazz Pharmaceuticals INC. | $107.06 | 2021-2025 | |
| Genzyme Corporation | $106.09 | 2023-2024 | |
| Clovis Oncology, INC. | $102.62 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $100.63 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.03 | 2020-2022 | |
| Array Biopharma INC | $86.03 | 2019-2024 | Mektovi, Lorbrena, Braftovi |
| Gilead Sciences, INC. | $83.87 | 2022-2024 | |
| Pfizer Pharmaceuticals LLC | $65.99 | 2019 | |
| Stemline Therapeutics INC. | $57.46 | 2025 | Orserdu |
| Springworks Therapeutics, INC. | $56.28 | 2024-2025 | Ogsiveo |
| Emd Serono, INC. | $54.11 | 2023-2024 | Bavencio |
| Kyowa Kirin, INC. | $50.00 | 2024-2025 | Poteligeo |
| Beone Medicines USA, INC. | $49.06 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $44.27 | 2020-2025 | Onivyde |
| Tolmar, INC. | $44.07 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $44.07 | 2025 | Rubraca |
| Karyopharm Therapeutics INC. | $27.54 | 2023 | Xpovio |
| Syndax Pharmaceuticals, INC. | $24.53 | 2025 | |
| Caris Mpi, INC. | $21.09 | 2025 | Mi Cancer Seek |
| Cti Biopharma Corp. | $21.03 | 2023 | Vonjo |
| Blueprint Medicines Corporation | $18.51 | 2024 | Ayvakit |
| Genmab U.S., INC. | $18.27 | 2023 | Epkinly |
| Deciphera Pharmaceuticals INC. | $13.56 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,188.32 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.